September is the beginning of a new season. It’s also important because it’s Menopause Awareness Month. Women go through many physical changes as they enter menopause. Some, like night sweats and hot flashes, are well-known and easy to talk about. Other changes, however, are more difficult to discuss.
Linda Williams, aged 71, experienced painful sexual experiences due to menopause. But she didn’t realize that her experience was caused by vulvar and/or vaginal Atrophy (VVA). The vagina can become more rigid and irritable after menopause due to hormonal changes. VVA affects approximately 50 percent of women after menopause. It can cause dryness, irritation and painful sex. Lubricants may temporarily reduce the pain of sex but don’t address the underlying cause.
Menopause-related pain in sex can be awkward to talk about with friends, partners, or healthcare professionals. “I don’t think women are comfortable talking about their symptoms which is unfortunate because painful sex due to menopause isn’t an inevitable part of aging,”Linda.
Linda’s nurse practitioner prescribed INTRAROSA® (prasterone), vaginal inserts for moderate to severe painful sex due to menopause. INTRAROSA prescriptions help to relieve pain and treat the underlying causes of painful sex after menopause.
“Painful sex due to menopause is common and treatable,”Linda’s nurse practitioner Dr. Lisa Chism DNP was Linda’s Clinical Director at Karmanos Cancer Institute’s Women’s Wellness Clinic. She is also a consultant for AMAG Pharmaceuticals. “I urge women to talk to their healthcare provider about their symptoms and find a treatment option that is right for them, just like Linda did.”
Indication
INTRAROSA vaginal Inserts are prescription medicines that women who have gone through menopause can use to relieve moderate to severe pain from sexual intercourse. They treat the effects of changes in the vaginal area and vagina as a result of menopause.
Important Safety Information
INTRAROSA contraindicated for women who have undiagnosed abnormal bleeding.
Estrogen can be a metabolite prasterone. Women with a history or suspicion of breast cancer should avoid exogenous estrogen. INTRAROSA was not studied in breast cancer survivors.
The most common adverse reaction that occurred in four 12-week placebo-controlled, randomized clinical trials was vaginal bleeding. One 52-week open-label clinical trials found that vaginal discharge was the most common adverse reaction with an incidence of?2 percent.
The FDA encourages you to report side effects from prescription drugs to them. Visit www.fda.gov/medwatchOr call 1-800-FDA-1088
Please read the complete article Prescribing Information.
Visit https://us.intrarosa.comFind out more about managing VVA.
